Compounds > ski 2053r
Page last updated: 2024-12-11

ski 2053r

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SKI 2053R: structure in first source; RN given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6918271
MeSH IDM0239684

Synonyms (6)

Synonym
AC-2111
ski-2053r
nsc-644591
ski 2053r
AKOS015964850
[(4r,5r)-5-(aminomethyl)-2-propan-2-yl-1,3-dioxolan-4-yl]methanamine;platinum;propanedioic acid

Research Excerpts

Actions

ExcerptReferenceRelevance
"SKI 2053R did not cause significant neurotoxicity or mucositis."( A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies.
Bang, YJ; Cho, YB; Heo, DS; Kim, DK; Kim, KH; Kim, NK; Kim, TY; Lee, JA; Park, YI; Shin, SG, 2001)		1.03

Treatment

ExcerptReferenceRelevance
"In SKI 2053R-treated groups, the time required for a mean tumor weight of 1,000 mg was 33.1 days in KATO III xenografts and 35.0 days in WiDr xenografts as compared with 30.2 and 27.2 days in CDDP-treated groups, respectively."( Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
Ahn, JS; Cho, YB; Hong, WS; Kim, DK; Kim, HT; Kim, KH; Kim, TS; Tai, JH, 1995)		0.81

Toxicity

ExcerptReferenceRelevance
" The results show that SKI 2053R is embryotoxic at a minimally maternally toxic dose in rats."( Embryotoxic effects of SKI 2053R, a new potential anticancer agent, in rats.
Chung, MK; Kim, JC; Roh, JK, )		0.75
"Heptaplatin is a newly developed platinum derivative which has been reported to be less toxic than cisplatin."( Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
Ahn, JH; Bahng, H; Chang, HM; Kang, WC; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, JS, 2002)		0.31
" Measures to more effectively prevent nephrotoxicity should be developed for the safe use of heptaplatin."( Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
Ahn, JH; Bahng, H; Chang, HM; Kang, WC; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, JS, 2002)		0.31
"The present study was conducted to test the possible teratogenic and toxic effects of anti-cancer drug heptaplatin (SKI 2053) on developing embryos and fetuses in gestating SWR/J mice."( Embryo-feto-toxicity of anticancer drug, heptaplatin in laboratory mice.
Abdel-Samad, MF; Abou-Tarboush, FM; Al-Ahmadi, BA; Al-Anazi, KM; Al-Faifi, MY; Farah, MA, 2010)		0.36

Compound-Compound Interactions

ExcerptReferenceRelevance
" Overall, the present study supports the clinical development of HTP in combination with low-dose PTX against HNSCC."( Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro.
Cho, YB; Kim, SY; Kuh, HJ; Lee, JW; Lee, SH; Park, JK, 2006)		0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (47.37)18.2507
2000's5 (26.32)29.6817
2010's5 (26.32)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.10 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (19.05%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (80.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		4.131nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
metoclopramide
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.		3.3911benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound		antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic
ondansetron
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.		3.3911carbazoles
platinum
Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.		2.1710elemental platinum;
nickel group element atom;
platinum group metal atom
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		2.110delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.0310taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
irinotecan
[no description available]		2.110carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
carboplatin
[no description available]		2.730
nedaplatin
nedaplatin: structure given in first source		2.1710
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Colon
[description not available]		02.4220
Colonic Neoplasms
Tumors or cancer of the COLON.		02.4220
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.4220
Adenocarcinoma, Basal Cell
[description not available]		04.8642
Leukocytopenia
[description not available]		04.3622
Cancer of Stomach
[description not available]		05.0452
Emesis
[description not available]		03.3911
Acute Disease
Disease having a short and relatively severe course.		03.3911
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		04.8642
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		04.3622
Leukopenia
A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).		04.3622
Proteinuria
The presence of proteins in the urine, an indicator of KIDNEY DISEASES.		03.3911
Stomach Neoplasms
Tumors or cancer of the STOMACH.		05.0452
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		03.3911
Carcinoma, Epidermoid
[description not available]		02.0210
Cancer of Larynx
[description not available]		02.0210
Cancer of Lung
[description not available]		04.341
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		02.0210
Laryngeal Neoplasms
Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.		02.0210
Lung Neoplasms
Tumors or cancer of the LUNG.		04.341
Cancer of Head
[description not available]		02.0310
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)		02.0310
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		01.9810
Leukemia L 1210
[description not available]		01.9810
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		01.9810
Carcinoma, Oat Cell
[description not available]		03.3811
Blood Diseases
[description not available]		03.3811
Hematologic Diseases
Disorders of the blood and blood forming tissues.		03.3811
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		03.3811
Carcinoma, Small Cell
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)		03.3811
Acute Liver Injury, Drug-Induced
[description not available]		03.3911
Benign Neoplasms
[description not available]		03.3911
Thrombopenia
[description not available]		03.3911
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.3911
Thrombocytopenia
A subnormal level of BLOOD PLATELETS.		03.3911
Chemical and Drug Induced Liver Injury
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.		03.3911